Rimegepant Phase 3 Trial for Migraine Prevention in Chinese Subjects Completes

A Phase 3 clinical trial (NCT05810038) investigating rimegepant for the prevention of migraine in Chinese subjects reached primary completion on August 25, 2025. This study, titled "A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects," aimed to evaluate the safety and effects of rimegepant in this specific patient population.

Background

The trial focused on rimegepant for migraine prevention. Migraine is a neurological condition characterized by recurrent headaches, often accompanied by other symptoms like sensitivity to light and sound. The completion of this study marks a step in gathering data on rimegepant's potential in the Chinese population.

Trial design

The study, identified as NCT05810038, was a Phase 3 trial that enrolled 787 participants. The trial investigated rimegepant in subjects diagnosed with migraine. Participants were male and female, 18 years of age or older, with at least a one-year history of migraine. They were randomly assigned to treatment groups, receiving either rimegepant or placebo during a 12-week Double-blind Treatment (DBT) Phase. The overall study duration was approximately 30 weeks, including four phases and eleven visits.

What this means

The primary completion of this Phase 3 trial for rimegepant indicates that all participants have finished their scheduled treatments and follow-up visits, and data collection for the primary endpoints is concluded. The next phase involves comprehensive data analysis to determine the safety and efficacy profile of rimegepant for migraine prevention in Chinese subjects. The results from this study will be important for understanding its potential clinical application in this demographic.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05810038, titled "A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects," was posted on 2025-08-25 on clinicaltrials.gov.